Pular para o conteúdo principal
Ranking Invest

CDTX - Cidara Therapeutics, Inc.

Segmento: HealthcareCidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Análise Ranking Invest

Valuation estimado
-$ 99.83 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 141.68 Mi

Dívida Líquida

-$ 165.48 Mi

L4T

-$ 180.73 Mi

MM4T

-7401.49%

Indicadores Básicos

ROE

-127.56%

Índices de Previsibilidade

Receita Líquida

G0.75

Lucro

E1.45

Margem

D0.83

Índices de Tendência

Receita Líquida

E-5.81

Lucro

F-5.56

Margem

B6.33

Índices de Endividamento

DIV/PAT

-1.17

DIV/L4T

0.92

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.